Atrasentan in Patients With Proteinuric Glomerular Diseases | MicrobiomeTrials← Back to trialsNCT04573920
Atrasentan in Patients With Proteinuric Glomerular Diseases
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2021-03-15Est. Completion: 2024-07-02
Enrollment target: 103 participants Locations- Kidney Disease Medical Group, Glendale, California, United States
- Academic Medical Research Institute, Los Angeles, California, United States
- North America Research Institute, San Dimas, California, United States
- Stanford U School Of Medicine, Stanford, California, United States
- Colorado Kidney Care Nephrology, Denver, Colorado, United States
- Northwest Louisiana Nephrology Research, Shreveport, Louisiana, United States
- Tufts Medical Center, Boston, Massachusetts, United States
- Uni of Minnesota Hos and Clinics, Minneapolis, Minnesota, United States
- DaVita Clinical Research, Las Vegas, Nevada, United States
- Mountain Kidney And Hyper Associa, Asheville, North Carolina, United States
- Brookview Hills Research Assoc, Winston-Salem, North Carolina, United States
- Baylor Scott and White, Dallas, Texas, United States
- Prolato Clinical Research Center, Houston, Texas, United States
- Milwaukee Nephrologists SC, Wauwatosa, Wisconsin, United States
- Novartis Investigative Site, Gosford, New South Wales, Australia
Other microbiome trials you might be interested in
Immunoglobulin A Nephropathy (IgAN)
In this study, researchers will learn more about the use of felzartamab in participants with immunoglobulin A nephropath…
Little Rock, United StatesEst. completion May 31, 2027
IgA Nephropathy
This is a phase IIa, multicenter, single-arm, open-label study to evaluate the safety and efficacy of XH-S003 in patient…
Beijing, ChinaCompleted Apr 23, 2026
Novartis Investigative Site, Herston, Queensland, AustraliaNovartis Investigative Site, Clayton, Victoria, AustraliaNovartis Investigative Site, Reservoir, Victoria, AustraliaNovartis Investigative Site, St Albans, Victoria, AustraliaNovartis Investigative Site, St Leonards, AustraliaNovartis Investigative Site, Roma, RM, ItalyNovartis Investigative Site, Cheonan, Chungcheongnam-do, South KoreaNovartis Investigative Site, Anyang-si, Gyeonggi-do, South KoreaNovartis Investigative Site, Seoul, Korea, South KoreaNovartis Investigative Site, Seoul, South KoreaNovartis Investigative Site, Seoul, South KoreaNovartis Investigative Site, Port de Sagunt, Valencia, SpainNovartis Investigative Site, Barcelona, SpainNovartis Investigative Site, Lugo, SpainNovartis Investigative Site, Madrid, SpainNovartis Investigative Site, Majadahonda, SpainNovartis Investigative Site, Sheffield, South Yorkshire, United KingdomNovartis Investigative Site, London, United KingdomRecruiting
Immunoglobulin A Nephropathy (IgAN)Complement 3 Glomerulopathy (C3G)IC-MPGN
This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults …
Shenzhen, ChinaEst. completion Jul 10, 2028